Repeat: Treatment.com AI and Aiyibotong collaborate to explore commercial opportunities for Clinical Decision Support in China and Far East
Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.
Key highlights:
- China's CDSS market expected to reach ~US$600 million by 2030
- Aiyibotong has installations in over 200 healthcare institutions in China
- Digital Health investment in China projected to hit US$45 billion in 2025
The collaboration focuses on:
- GLM content localization and alignment with Chinese medical consensus
- Technology licensing and CDSS platform integration
- Co-marketing initiatives in China
- Development of AI-based CDSS for the global market
Treatment.com AI (TREIF) ha firmato un Accordo di Collaborazione con Beijing Aiyi Botong Information Technology (Aiyibotong) per esplorare opportunità commerciali per i Sistemi di Supporto alle Decisioni Cliniche (CDSS) nei mercati della Cina e dell'Estremo Oriente. L'obiettivo della partnership è combinare la Biblioteca Globale di Medicina (GLM) di Treatment con la tecnologia CDSS di Aiyibotong.
Principali punti salienti:
- Il mercato CDSS della Cina è previsto raggiungere ~600 milioni di dollari USA entro il 2030
- Aiyibotong ha installazioni in oltre 200 istituzioni sanitarie in Cina
- Gli investimenti nella Salute Digitale in Cina dovrebbero toccare 45 miliardi di dollari USA nel 2025
La collaborazione si concentra su:
- Localizzazione dei contenuti GLM e allineamento con il consenso medico cinese
- Licenza tecnologica e integrazione della piattaforma CDSS
- Iniziative di co-marketing in Cina
- Sviluppo di CDSS basati su AI per il mercato globale
Treatment.com AI (TREIF) ha firmado un Acuerdo de Colaboración con Beijing Aiyi Botong Information Technology (Aiyibotong) para explorar oportunidades comerciales para los Sistemas de Soporte a la Decisión Clínica (CDSS) en los mercados de China y el Lejano Oriente. La asociación tiene como objetivo combinar la Biblioteca Global de Medicina (GLM) de Treatment con la tecnología CDSS de Aiyibotong.
Puntos clave:
- Se espera que el mercado de CDSS en China alcance ~600 millones de dólares estadounidenses para 2030
- Aiyibotong tiene instalaciones en más de 200 instituciones de salud en China
- Se proyecta que la inversión en Salud Digital en China alcance 45 mil millones de dólares estadounidenses en 2025
La colaboración se centra en:
- Localización de contenido GLM y alineación con el consenso médico chino
- Licenciamiento de tecnología e integración de la plataforma CDSS
- Iniciativas de co-marketing en China
- Desarrollo de CDSS basados en IA para el mercado global
Treatment.com AI (TREIF)는 베이징 아이이봇통 정보기술(Aiyibotong)과 협력 협정을 체결하여 중국 및 극동 시장에서 임상 의사결정 지원 시스템(CDSS)의 상업적 기회를 탐색합니다. 파트너십의 목표는 Treatment의 글로벌 의학 라이브러리(GLM)와 Aiyibotong의 CDSS 기술을 결합하는 것입니다.
주요 하이라이트:
- 중국의 CDSS 시장은 2030년까지 약 6억 달러에 이를 것으로 예상됨
- Aiyibotong은 중국의 200개 이상의 의료 기관에 설치됨
- 2025년까지 중국의 디지털 헬스 투자액은 450억 달러에 이를 것으로 예상됨
협력의 초점은:
- GLM 콘텐츠의 현지화 및 중국 의료 합의와의 정렬
- 기술 라이선스 및 CDSS 플랫폼 통합
- 중국 내 공동 마케팅 이니셔티브
- 글로벌 시장을 위한 AI 기반 CDSS 개발
Treatment.com AI (TREIF) a signé un Accord de Collaboration avec Beijing Aiyi Botong Information Technology (Aiyibotong) pour explorer des opportunités commerciales pour les Systèmes d'Aide à la Décision Clinique (CDSS) sur les marchés chinois et de l'Extrême-Orient. L'objectif du partenariat est de combiner la Bibliothèque Médicale Globale (GLM) de Treatment avec la technologie CDSS d'Aiyibotong.
Points clés:
- Le marché des CDSS en Chine devrait atteindre environ 600 millions de dollars américains d'ici 2030
- Aiyibotong possède des installations dans plus de 200 établissements de santé en Chine
- Les investissements dans la santé numérique en Chine devraient atteindre 45 milliards de dollars américains en 2025
La collaboration se concentre sur:
- Localisation du contenu GLM et alignement avec le consensus médical chinois
- Licences technologiques et intégration de la plateforme CDSS
- Initiatives de co-marketing en Chine
- Développement de CDSS basés sur l'IA pour le marché mondial
Treatment.com AI (TREIF) hat eine Kooperation mit Beijing Aiyi Botong Information Technology (Aiyibotong) unterzeichnet, um kommerzielle Möglichkeiten für Klinische Entscheidungsunterstützungssysteme (CDSS) in China und den Märkten des Fernen Ostens zu erkunden. Ziel der Partnerschaft ist es, die Globale Medizinbibliothek (GLM) von Treatment mit der CDSS-Technologie von Aiyibotong zu kombinieren.
Wichtige Highlights:
- Der CDSS-Markt in China wird voraussichtlich bis 2030 etwa 600 Millionen US-Dollar erreichen
- Aiyibotong hat Installationen in über 200 Gesundheitseinrichtungen in China
- Die Investitionen in digitale Gesundheit in China werden voraussichtlich bis 2025 45 Milliarden US-Dollar erreichen
Die Zusammenarbeit konzentriert sich auf:
- Lokalisierung der GLM-Inhalte und Anpassung an den chinesischen medizinischen Konsens
- Technologielizenzierung und Integration der CDSS-Plattform
- Gemeinsame Marketinginitiativen in China
- Entwicklung von KI-basierten CDSS für den globalen Markt
- Strategic entry into China's large CDSS market (~US$600M by 2030)
- Partnership with established player having 200+ healthcare institution installations
- No costs associated with the collaboration agreement
- Access to China's growing Digital Health market (US$45B by 2025)
- Potential for global market expansion through combined AI technologies
- No immediate revenue generation specified from the partnership
- Early-stage agreement with no defined timeline for implementation
- Potential challenges in adapting technology to Chinese medical consensus
- Market for Clinical Decision Support (CDSS) in China is ~US
$600 million by 2030 - Aiyibotong has installed systems in >200 healthcare institutions in China
- Aiyibotong and Treatment.com AI both using proprietary artificial intelligence (AI) and Machine Learning (ML) platforms
- Co-marketing opportunities in China
- Combining Aiyibotong’s CDSS with Treatment AI's Global Library of Medicine will look to create further differentiation and increased market share for Aiyibotong in the China and Far East markets
VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has recently signed a Collaborative Agreement on with Beijing Aiyi Botong Information Technology Ltd Limited (“Aiyibotong”). Each organization has a focus in providing enhanced clinical decision support for both healthcare professionals and patients, using innovative technologies including AI and machine learning. Aiyibotong and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to enhance patient support in China and other Far East countries.
Investment in Digital Health in China is expected to reach US
Treatment is partnering with Aiyibotong, a China based healthcare information technology company focused on providing clinical decision supporting solutions (CDSS) for medical professionals in both large hospitals as well as clinics. Its CDSS has been developed on proprietary AI technologies, natural language processing (NLP) as well as machine learning algorithms and knowledge graph. Since its establishment in 2019, it has installed its CDSS systems in more than 200 healthcare institutions. The company is currently expanding its product portfolio to cover broader clinical quality assurance systems including Electronic Medical Record (EMR) QA, Venous Thromboembolism (VTE) Risk Management and Multidisciplinary Team (MDT) assistants.
The envisaged areas of collaboration include:
- Aiyibotong assisting Treatment in localization of its Global Library of Medicine (GLM) content and alignment with Chinese medical consensus;
- Aiyibotong licensing Treatment technology and integration with its’ CDSS platform
- Co-marketing in China, targeting healthcare institutions and universities;
- Co-developing an AI based CDSS for the global market, combining Aiyibotong’s value of 10 years of experience in the sector and accumulated data and know-how, together with Treatment’s technology and global medical professionals.
The Agreement was signed on 19th February 2025 and there are no costs associated with this Agreement.
Treatment’s Global Library of Medicine (GLM) enables healthcare professionals to capture a patient’s presenting symptoms, past medical history and through AI and smart proprietary algorithms, formulate the most likely diagnosis and suggest the most important tests/exams that should be performed. This history can then be shared with the patient’s healthcare professional in real time and also programmed to help with triaging patients more efficiently.
The Agreement was signed on 19th February 2025 and there are no costs associated with this Agreement. Treatment and Aiyibotong have already started to explore mutually beneficial opportunities through China and the Far East regions.
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “We look forward to working with Aiybotong to expand the GLM to new languages and opportunities in Asia and the Far East. Amongst the solutions we believe can augment Aiyibotong’s product lines, our new AI voice agent/assistant speaking in regional languages and with local dialects, can help onboard and triage marginalized and underserved patients in the community.”
Chenjin Liu, General Manager of Aiyibotong comments: “Aiyibotong is in the process of adopting new LLM technologies in our CDSS product lines and will use the ‘knowledge + data’ hybrid model to drive our system so that the LLM can make our product more AI empowered while our existing knowledge graph and expert system will effectively limit the hallucination in LLM. We’re excited to collaborate with Treatment as their Global Library of Medicine can be a great value add to enhance our expert system. In addition to the China market, we see this hybrid model driven CDSS can be a global product.”
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services, go to: www.treatment.com or email: info@treatment.com
About Aiyibotong
Aiyibotong is a Chinese company specialized in developing and marketing Clinical Decision Support solutions to healthcare institutions. Its CDSS is currently based on a natural language process model and knowledge graph, and in the process of adoption of LLM technologies. Its CDSS provides clinical suggestions for over 9,000 diseases. Aiyibotong’s CDSS is currently integrated with most of the main Chinese HIS and EMR systems installed in both large hospitals and small clinics. To learn more about Aiyibotong’s products and services, go to: www.aiyibotong.com or email: support@aiyibotong.com
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is the expected market size for Clinical Decision Support Systems (CDSS) in China by 2030 for TREIF?
How many healthcare institutions currently use Aiyibotong's CDSS systems?
What are the main collaboration areas between Treatment.com AI (TREIF) and Aiyibotong?
When was the collaboration agreement signed between TREIF and Aiyibotong?
What is the projected Digital Health investment in China for 2025?
